Painting in the psychedelics field

We’re entirely remaking the courses website to include individual pages for courses and better search functionality.

Update: The new courses site is live (middle/end of January) and will be fully filled in over the course of February.

Based on three years of experience studying the science of psychedelics, I want to launch a mini course that introduces people to the field. The course would cover both the basics of the science and my/our perspective on where the field is going (e.g. what results to expect from ongoing trials).

The goal is to make the course low-priced (think 20-50 euros) so that many can use it as a good starting point in the industry or to get an overview if you’re focussed on your specific area.

The database (individual data points) is starting to be ‘complete’. We are now looking into getting the data in more overview pages.

For example, we are building an overview of all the ‘original’ studies, showing how many people have gone through the trials. Another project we’re working on is showcasing how many studies have been done for specific topics (e.g. depression) and writing a longer explainer on this topic.

Update: The next visualisation is live, see here.

Over the last few months, we’ve been highlighting more and more what companies are doing in the psychedelic space. Now we also want to expand the information collected in our database.

Just as we’ve done for papers & trials, we will provide more information on the companies working on psychedelics.

Next to the individual data points, we will also expand to cover more company data in overview pages.

Update: There were some updates on this front, but I spent more time on other projects.

Now that we have a basic version of nearly all topics covered by psychedelics, we want to dive deeper in partnership with some of the best psychedelic companies.

We have now (mid-May 2022) finished one paid report (to be published after review) and have a much more extensive report in the works together with a partner.

Next to that partnership, we remain open to partnering on other reports or paid engagements.

Over the last few months, we’ve been highlighting more and more what companies are doing in the psychedelic space. Now we also want to expand the information collected in our database.

Just as we’ve done for papers & trials, we will provide more information on the companies working on psychedelics.

Next to the individual data points, we will also expand to cover more company data in overview pages.

The reports bring to life the information from the databases, they are each an introduction to a specific topic (e.g. depression), compound (e.g. MDMA), or country (e.g. Switzerland).

Next to finishing our first versions of the reports, we are actively looking for collaborators to help make more detailed versions of the reports.

Since Q3 2021 we’ve been working on redesigning Blossom. This includes the new logo and styling, but also a new way of displaying the databases and individual pages (e.g. of a single paper).

The biggest changes here will be the search and individual pages for papers and companies that we’re working on behind the scenes.

Running since 2019, Blossom has been funded primarily by the personal funds of our founder. We are now actively working on recruiting partners to work with as well as emploring individual users of the database to chip in if the information we provide is valuable to them.

Contact us if you’re interested in cooperating.